Scientific results & research

Reverse Diabetes2 Now is a curative treatment programme, developed by Stichting Voeding Leeft, focused on reversing type 2 diabetes. Reverse Diabetes2 Now works with lifestyle and uses nutrition, exercise, sleep and relaxation as therapy.

To measure the effectiveness of the programme Reverse Diabetes2 Now and in order to compare the programme to regular diabetes care, a scientific study is underway, conducted by the Louis Bolk Institute, an independent research institute. The research study is led by Dr. Ir. Gerda Pot, with 1900 participants from 2017 to 2019.

The research tests the following hypotheses:

  • Participants use less medication and have healthier blood values (HbA1C) two years after the start of the programme.
  • Participants feel better two years after the start of the programme.
  • Participants need less care and their care expenditure decreases.

Participants of Reverse Diabetes2 apply to join the programme themselves. Participants are not randomised: there is no control group that has been offered an alternative intervention. All 1.900 participants who start the Reverse Diabetes2 Now programme between 2017 and 2019 are invited to participate in the research.  When entering the research study, participants are followed for two years. The research study started in January 2017.  The last group will start mid 2019, hence the research will finish at the end of 2021.

Reverse Diabetes2 Now is in charge of the practical execution of the programme. It holds no research data, and has no access to research data on an individual level.

Would you like to read the whole Louis Bolk Insitute research report?

Fill out the form below to receive the latest research report from the Louis Bolk Institute

*Louis Bolk Institute report “4th intermediate results of Keer Diabetes2 Om”. Scientific research measuring the effect of the Reverse Diabetes2 Now program of Voeding Leeft in The Netherlands, together with health Insurance partner VGZ. Publication in preparation. The report is based on participants from whom data is available. Because of loss to follow up and the stepped care model, the number of results per datapoint varies.